Literature DB >> 12685058

Venous thromboembolism prophylaxis in the medically ill patient.

Franklin A Michota1.   

Abstract

All general medical patients should be assessed for clinical risk factors for VTE. The ACCP has recommended that general medical patients with clinical risk factors receive either LDUH twice or three times daily or once-daily LMWH. Current evidence suggests that twice-daily LDUH may not be efficacious enough in the acutely ill medical inpatient. LDUH three times daily may be efficacious in most medical patients; however, it is associated with an increased risk for bleeding. The preferred strategy for prevention in the medically ill population at high to very high risk for VTE is LMWH. For patients who have a high to very high risk for bleeding, nonpharmacologic strategies such as ES or IPC devices are recommended.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12685058     DOI: 10.1016/s0272-5231(02)00078-3

Source DB:  PubMed          Journal:  Clin Chest Med        ISSN: 0272-5231            Impact factor:   2.878


  4 in total

Review 1.  Prevention of venous thromboembolism in medically ill patients: a clinical update.

Authors:  Alexander G G Turpie; Alain Leizorovicz
Journal:  Postgrad Med J       Date:  2006-12       Impact factor: 2.401

2.  A five-year, retrospective, comparison review of survival in neurosurgical patients diagnosed with venous thromboembolism and treated with either inferior vena cava filters or anticoagulants.

Authors:  Amanda J Ghanim; Constantine Daskalakis; David J Eschelman; Walter K Kraft
Journal:  J Thromb Thrombolysis       Date:  2007-03-24       Impact factor: 2.300

3.  Benefits and risks of low molecular weight heparin in patients with acute exacerbation of chronic obstructive pulmonary disease: a meta-analysis of randomized controlled trials.

Authors:  Mingjin Yang; Ying Xu; Hong Chen; Zhibo Xu; Fengming Luo
Journal:  Inflammopharmacology       Date:  2019-10-31       Impact factor: 4.473

4.  Antifactor Xa activity in critically ill patients receiving antithrombotic prophylaxis with standard dosages of certoparin: a prospective, clinical study.

Authors:  Stefan Jochberger; Viktoria Mayr; Günter Luckner; Dietmar R Fries; Andreas J Mayr; Barbara E Friesenecker; Ingo Lorenz; Walter R Hasibeder; Hanno Ulmer; Wolfgang Schobersberger; Martin W Dünser
Journal:  Crit Care       Date:  2005-08-09       Impact factor: 9.097

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.